SOCS1 abrogates IFN's antiviral effect on hepatitis C virus replication

Antiviral Research

Volumn 97, Issue 2, 2013, Pages 101-107

  Shao, Run Xuan ^b   Zhang, Leiliang ^a,b   Hong, Zhi ^a   Goto, Kaku ^b   Cheng, Du ^b   Chen, Wen Chi ^b   Jilg, Nikolaus ^b   Kumthip, Kattareeya ^b   Fusco, Dahlene N ^b   Peng, Lee F ^b   Chung, Raymond T ^b  

^a INSTITUTE OF PATHOGEN BIOLOGY   (China)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Hepatitis C virus; Interferon; ISG; JFH1; SOCS1

Indexed keywords

ALPHA INTERFERON; SUPPRESSOR OF CYTOKINE SIGNALING 1;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; GENE OVEREXPRESSION; GENE SILENCING; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; UPREGULATION; VIRUS INHIBITION; VIRUS REPLICATION;

CELL LINE; HEPACIVIRUS; HEPATOCYTES; HOST-PATHOGEN INTERACTIONS; HUMANS; INTERFERON-ALPHA; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; VIRUS REPLICATION;

HEPATITIS C VIRUS;

EID: 84871892804     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.12.001     Document Type: Article

References (27)

1. Akhtar L.N., Benveniste E.N. Viral exploitation of host SOCS protein functions. J. Virol. 2011, 85:1912-1921.
2. Alexander W.S., Starr R., Fenner J.E., Scott C.L., Handman E., Sprigg N.S., Corbin J.E., Cornish A.L., Darwiche R., Owczarek C.M., Kay T.W., Nicola N.A., Hertzog P.J., Metcalf D., Hilton D.J. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 1999, 98:597-608.
3. Bostan N., Mahmood T. An overview about hepatitis C: a devastating virus. Crit. Rev. Microbiol. 2010, 36:91-133.
4. Chung R.T., Andersen J., Volberding P., Robbins G.K., Liu T., Sherman K.E., Peters M.G., Koziel M.J., Bhan A.K., Alston B., Colquhoun D., Nevin T., Harb G., van der Horst C. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N. Engl. J. Med. 2004, 351:451-459.
5. Croker B.A., Krebs D.L., Zhang J.G., Wormald S., Willson T.A., Stanley E.G., Robb L., Greenhalgh C.J., Forster I., Clausen B.E., Nicola N.A., Metcalf D., Hilton D.J., Roberts A.W., Alexander W.S. SOCS3 negatively regulates IL-6 signaling in vivo. Nat. Immunol. 2003, 4:540-545.
6. Darnell J.E., Kerr I.M., Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264:1415-1421.
7. Fu X.Y., Kessler D.S., Veals S.A., Levy D.E., Darnell J.E. ISGF3, the transcriptional activator induced by interferon alpha, consists of multiple interacting polypeptide chains. Proc. Natl. Acad. Sci. USA 1990, 87:8555-8559.
8. Fujimoto M., Naka T. SOCS1, a negative regulator of cytokine signals and TLR responses, in human liver diseases. Gastroenterol. Res. Pract. 2010, 2010:470468.
9. Fusco D.N., Chung R.T. Novel therapies for hepatitis C: insights from the structure of the virus. Annu. Rev. Med. 2012, 63:373-387.
10. Giordanetto F., Kroemer R.T. A three-dimensional model of suppressor of cytokine signalling 1 (SOCS-1). Protein Eng. 2003, 16:115-124.
11. Hong F., Jaruga B., Kim W.H., Radaeva S., El-Assal O.N., Tian Z., Nguyen V.A., Gao B. Opposing roles of STAT1 and STAT3 in T cell-mediated hepatitis: regulation by SOCS. J. Clin. Invest. 2002, 110:1503-1513.
12. McHutchison J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.M., Rustgi V.K., Goodman Z.D., Ling M.H., Cort S., Albrecht J.K. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis interventional therapy group. N. Engl. J. Med. 1998, 339:1485-1492.
13. McHutchison J.G., Lawitz E.J., Shiffman M.L., Muir A.J., Galler G.W., McCone J., Nyberg L.M., Lee W.M., Ghalib R.H., Schiff E.R., Galati J.S., Bacon B.R., Davis M.N., Mukhopadhyay P., Koury K., Noviello S., Pedicone L.D., Brass C.A., Albrecht J.K., Sulkowski M.S. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. 2009, 361:580-593.
14. Moorman J., Dong Z.P., Ni L., Zhang C., Borthwick T., Yao Z.Q. Abnormal B-cell activation associated with TALL-1 over-expression and SOCS-1 suppression during chronic hepatitis C virus infection. Immunology 2009, 128:227-235.
15. Piganis R.A., De Weerd N.A., Gould J.A., Schindler C.W., Mansell A., Nicholson S.E., Hertzog P.J. Suppressor of cytokine signaling (SOCS) 1 inhibits type I interferon (IFN) signaling via the interferon alpha receptor (IFNAR1)-associated tyrosine kinase Tyk2. J. Biol. Chem. 2011, 286:33811-33818.
16. Schaefer E.A., Chung R.T. Anti-hepatitis C virus drugs in development. Gastroenterology 2012, 142(1340-1350):e1341.
17. Schoggins J.W., Wilson S.J., Panis M., Murphy M.Y., Jones C.T., Bieniasz P., Rice C.M. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011, 472:481-485.
18. Sedeno-Monge V., Santos-Lopez G., Rocha-Gracia R.C., Melendez-Mena D., Ramirez-Mata A., Vallejo-Ruiz V., Reyes-Leyva J. Quantitative analysis of interferon alpha receptor subunit 1 and suppressor of cytokine signaling 1 gene transcription in blood cells of patients with chronic hepatitis C. Virol. J. 2010, 7:243.
19. Shao R.X., Zhang L., Peng L.F., Sun E., Chung W.J., Jang J.Y., Tsai W.L., Hyppolite G., Chung R.T. Suppressor of cytokine signaling 3 suppresses hepatitis C virus replication in an mTOR-dependent manner. J. Virol. 2010, 84:6060-6069.
20. Sporri B., Kovanen P.E., Sasaki A., Yoshimura A., Leonard W.J. JAB/SOCS1/SSI-1 is an interleukin-2-induced inhibitor of IL-2 signaling. Blood 2001, 97:221-226.
21. Stark G.R., Darnell J.E. The JAK-STAT pathway at twenty. Immunity 2012, 36:503-514.
22. Sun R., Park O., Horiguchi N., Kulkarni S., Jeong W.I., Sun H.Y., Radaeva S., Gao B. STAT1 contributes to dsRNA inhibition of liver regeneration after partial hepatectomy in mice. Hepatology 2006, 44:955-966.
23. Theofilopoulos A.N., Baccala R., Beutler B., Kono D.H. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu. Rev. Immunol. 2005, 23:307-336.
24. Vlotides G., Sorensen A.S., Kopp F., Zitzmann K., Cengic N., Brand S., Zachoval R., Auernhammer C.J. SOCS-1 and SOCS-3 inhibit IFN-alpha-induced expression of the antiviral proteins 2,5-OAS and MxA. Biochem. Biophys. Res. Commun. 2004, 320:1007-1014.
25. Wakita T., Pietschmann T., Kato T., Date T., Miyamoto M., Zhao Z., Murthy K., Habermann A., Krausslich H.G., Mizokami M., Bartenschlager R., Liang T.J. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 2005, 11:791-796.
26. Zhang L., Jilg N., Shao R.X., Lin W., Fusco D.N., Zhao H., Goto K., Peng L.F., Chen W.C., Chung R.T. IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway. J. Hepatol. 2011, 55:289-298.
27. Zhao H., Lin W., Kumthip K., Cheng D., Fusco D.N., Hofmann O., Jilg N., Tai A.W., Goto K., Zhang L., Hide W., Jang J.Y., Peng L.F., Chung R.T. A functional genomic screen reveals novel host genes that mediate interferon-alpha's effects against hepatitis C virus. J. Hepatol. 2012, 56:326-333.